S3: Evolution of MDM2 and TP53 status over time of 5 patients affected by MDM2-amplified GBM. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i>-Amplified and <i>TP53</i> Wild-type Glioblastomas

<p>S3: Evolution of MDM2 and TP53 status over time of 5 patients affected by MDM2-amplified GBM.</p>